Crestchem Limited reported a significant turnaround in profitability for its first quarter of FY27, with standalone net profit surging 182% year-on-year to ₹98.29 lakh. The Ahmedabad-based nutrition chemical manufacturer saw revenue from operations climb 82% to ₹917.89 lakh, driven by stronger operational performance compared to the previous fiscal period.

The Board of Directors approved the unaudited standalone and consolidated financial results on August 12, 2026. The results were reviewed by Samir M. Shah & Associates, the company’s statutory auditors, in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In compliance with Regulation 47 of the same regulations, the company published the newspaper advertisement for these unaudited financial results on August 14, 2026, in Free Press Gujarat and Lokmitra.

Financial Performance Highlights

Standalone profit before tax (PBT) rose sharply to ₹136.19 lakh from ₹47.03 lakh in Q1FY26. This improvement was supported by robust top-line growth and controlled expense management. Cost of materials consumed increased proportionally with revenue but remained contained relative to income growth.

On a consolidated basis, which includes subsidiary Oleo Biosciences Private Limited, net profit for the quarter was ₹94.16 lakh, up 170% from ₹34.80 lakh in the corresponding quarter of FY26. Consolidated revenue from operations reached ₹925.69 lakh, compared to ₹503.09 lakh reported earlier.

What the Numbers Show

A key analytical observation is the divergence between revenue growth and operating leverage. While revenue grew 82%, total expenses increased only 71% year-on-year (from ₹468.87 lakh to ₹801.30 lakh). This indicates improved operating efficiency, as cost structures did not scale linearly with sales volume. Additionally, other income contributed ₹19.60 lakh to the bottom line, representing approximately 20% of the final net profit, highlighting a continued reliance on non-operating returns alongside core business gains.

The company operates in a single segment: Nutrition-Chemical Industries. Paid-up equity share capital remained unchanged at ₹300.00 lakh. Basic earnings per share (EPS) stood at ₹3.28, significantly higher than the ₹1.16 recorded in Q1FY26.

Crestchem Limited shareholders unanimously approved a final dividend of ₹1.50 per equity share for FY26 and reappointed key management members at its 34th Annual General Meeting (AGM) on August 6, 2026. The meeting, conducted via video conferencing, saw 85 members cast votes representing 968,844 shares for the financial statements and dividend resolutions, with 100% support. This outcome reinforces shareholder confidence in the company’s governance structure and capital return strategy for the fiscal year ended March 31, 2026.

The voting process was scrutinized by Mehul K. Raval of Mehul Raval & Associates, appointed under Section 108 of the Companies Act, 2013. Remote e-voting via the Central Depository Services Limited (CDSL) platform ran from August 3 to August 5, 2026, while live e-voting occurred during the AGM. The results were submitted to BSE Limited on August 7, 2026, pursuant to Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Voting Results by Resolution

All ordinary and special resolutions placed before the members passed with significant majorities. The financial statements and dividend declaration received unanimous support from all participating members. Reappointment resolutions for directors and related-party remuneration approvals secured over 98% support.

Key Governance Decisions

Shareholders approved the reappointment of Dipak Narendraprasad Patel as Managing Director for five years from July 1, 2026, to June 30, 2031. Additionally, Nirmit Dipak Patel was reappointed as Executive Director for five years from April 1, 2026, to March 31, 2031. The Board also sought approval for the remuneration of Parul Dipak Patel (Manager Administration) and Tansi Nirmit Patel (Secretarial & Accounts Assistant), both relatives of the directors, for five-year terms starting July 1, 2026, and April 1, 2026, respectively. These appointments were approved under Section 188 of the Companies Act, 2013.

Furthermore, shareholders authorized investments in subsidiary companies within permissible limits under Section 186 of the Companies Act, 2013. Chairman Dipak Narendraprasad Patel noted that no adverse comments were raised in the Auditor’s or Secretarial Audit Reports, indicating robust compliance with corporate governance standards.